Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
ESC Heart Failure|September 6, 2021
Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failureTsunenori Saito, Naoko Saito Sato, Kosuke Mozawa, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 12, 2018
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: RationaleYoshiaki Kubota, Takeshi Yamamoto, Shuhei Tara, et al.Circulation Reports|December 19, 2022
External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening - A Retrospective Cohort StudyYukihiro Watanabe, Hiroshige Murata, Hitoshi Takano, et al.Circulation Reports|May 11, 2026
Machine Learning Models Incorporating Nursing Care Needs to Predict 180-Day Prognosis in Patients With Heart Failure: Validation With Discrimination and Calibration AnalysesTakuya Nishino, Katsuhito Kato, Shuhei Tara, et al.Journal of Atherosclerosis and Thrombosis|May 29, 2024
A Novel Risk Score for Major Bleeding in Japanese Patients with Non-Valvular Atrial Fibrillation: The J-RISK AF StudyMasaharu Akao, Hirofumi Tomita, Michikazu Nakai, et al.ESC Heart Failure|July 8, 2021
Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitusKosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, et al.Journal of Cardiac Failure|August 23, 2021
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY TrialYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 8, 2021
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes MellitusYu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, et al.European Heart Journal Open|December 30, 2022
Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AFEitaro Kodani, Hirofumi Tomita, Michikazu Nakai, et al.Circulation Journal : Official Journal of the Japanese Circulation Society|March 25, 2021
A Novel Risk Stratification System for Ischemic Stroke in Japanese Patients With Non-Valvular Atrial FibrillationKen Okumura, Hirofumi Tomita, Michikazu Nakai, et al.Pageof 9